Thalacy

Thalacy is a preclinical-stage biotechnology company focused on developing novel small-molecule therapies for disorders of iron metabolism. The company's research centers on the hepcidin-ferroportin axis, a critical pathway for regulating systemic iron levels in the body. Thalacy is primarily developing oral hepcidin mimetics designed to treat iron overload in conditions such as beta-thalassemia and hereditary hemochromatosis, as well as to manage erythropoiesis in polycythemia vera. Founded on pioneering research from the Children's Hospital of Philadelphia, the company aims to provide more effective and convenient treatment options for patients suffering from iron-related diseases.